The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects

Mechanisms of Pharmacokinetic Enhancement Between Ritonavir and Saquinavir; Micro/Small Dosing Tests Using Midazolam (CYP3A4), Fexofenadine (p-Glycoprotein), and Pravastatin (OATP1B1) as Probe Drugs

(2013) Ichiro Ieiri et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin

(2012) Sara K. Quinney et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Steady-State Pharmacokinetics of Etravirine and Lopinavir/Ritonavir Melt Extrusion Formulation, Alone and in Combination, in Healthy HIV-Negative Volunteers

(2012) Monika Schöller-Gyüre et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics and Short-Term Safety of Etravirine in Combination With Fluconazole or Voriconazole in HIV-Negative Volunteers

(2012) Thomas N. Kakuda et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice

(2012) J. Jurica et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Pharmacokinetic Interactions of Maraviroc with Darunavir-Ritonavir, Etravirine, and Etravirine-Darunavir-Ritonavir in Healthy Volunteers: Results of Two Drug Interaction Trials

(2011) Thomas N. Kakuda et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Development of a quantification method for digoxin, a typical P-glycoprotein probe in clinical and non-clinical studies, using high performance liquid chromatography–tandem mass spectrometry: The usefulness of negative ionization mode to avoid competitive adduct-ion formation

(2011) Hideki Hirabayashi et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Interaction Potential of Etravirine with Drug Transporters AssessedIn Vitro

(2010) Nadine Cécile Luise Zembruski et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical perspective on antiretroviral drug–drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine

(2010) Thomas N Kakuda et al.   ANTIVIRAL THERAPY

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials

(2010) Christine Katlama et al.   ANTIVIRAL THERAPY

Evaluation of In Vivo P-Glycoprotein Phenotyping Probes

(2010) Joseph D. Ma et al.   CLINICAL PHARMACOKINETICS

Pharmacokinetic Interactions between Etravirine and Non-Antiretroviral Drugs

(2010) Thomas N. Kakuda et al.   CLINICAL PHARMACOKINETICS

An Evaluation of the Drug Interaction Potential of Pazopanib, an Oral Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, Using a Modified Cooperstown 5+1 Cocktail in Patients With Advanced Solid Tumors

(2010) B C Goh et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Simultaneous determination of tolbutamide, omeprazole, midazolam and dextromethorphan in human plasma by LC–MS/MS—A high throughput approach to evaluate drug–drug interactions

(2010) Wei Zhang et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A

(2009) Sandrine Turpault et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Clinical Pharmacokinetics and Pharmacodynamics of Etravirine

(2009) Monika Schöller-Gyüre et al.   CLINICAL PHARMACOKINETICS

Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone

(2009) Monika Schöller-Gyüre et al.   CONTRACEPTION

Caffeine Metabolic Ratios for the In Vivo Evaluation of CYP1A2, N-acetyltransferase 2, Xanthine Oxidase and CYP2A6 Enzymatic Activities

(2009) Nancy Hakooz   CURRENT DRUG METABOLISM

Drug–Drug Interactions Mediated Through P-Glycoprotein: Clinical Relevance and In Vitro–In Vivo Correlation Using Digoxin as a Probe Drug

(2008) KS Fenner et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS